Betalutin

Unassigned

New Medicines

Relapsed/anti-CD20 refractory follicular lymphoma - third-line or greater

Information

Radiopharmaceutical
Nordic Nanovector ASA
Nordic Nanovector ASA

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials
Yes
Yes

Category

First-in-class, beta-emitting anti-CD37 antibody-radionuclide-conjugate in a ready-to-use formulation. Following cell binding and internalisation, betalutin provides primary anti-tumour activity through targeted radiation-induced DNA disruption.
Annual incidence of follicular lymphomas has increased from 2-3 per 100,000 during the 1950s to 5-7 per 100,000 recently [1].
Relapsed/anti-CD20 refractory follicular lymphoma - third-line or greater
Intravenous